Heterocyclic Compounds, 4 or More Rings
"Heterocyclic Compounds, 4 or More Rings" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include four or more fused rings. Both aromatic or non-aromatic ring structures are included in this category.
| Descriptor ID |
D006576
|
| MeSH Number(s) |
D03.633.400
|
| Concept/Terms |
Heterocyclic Compounds, 4 or More Rings- Heterocyclic Compounds, 4 or More Rings
- Heterocyclic Compounds with 4 or More Rings
- Heterocyclic Cpds, 4 or More Rings
- Heterocyclic Compounds with Four or More Rings
Heterocyclic Compounds, 5-Ring- Heterocyclic Compounds, 5-Ring
- 5-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 5 Ring
- Heterocyclic Cpds, 5 Ring
- Five Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Five-Ring
- Fused Heterocyclic Compounds, Five Ring
Heterocyclic Compounds, 4-Ring- Heterocyclic Compounds, 4-Ring
- 4-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 4 Ring
- Heterocyclic Cpds, 4 Ring
- Four Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Four-Ring
- Fused Heterocyclic Compounds, Four Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 4 or More Rings".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 4 or More Rings".
This graph shows the total number of publications written about "Heterocyclic Compounds, 4 or More Rings" by people in this website by year, and whether "Heterocyclic Compounds, 4 or More Rings" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterocyclic Compounds, 4 or More Rings" by people in Profiles.
-
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer. Expert Rev Anticancer Ther. 2025 Jan; 25(1):27-40.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 Nov 22; 79(5):1258-1261.
-
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028.
-
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol. 2024 06 13; 31(6):3342-3349.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 Sep; 172:340-348.
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 07 01; 8(7):1047-1052.
-
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 07 01; 28(13):2762-2770.
-
Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 12 14; 5(23):5332-5343.